Currently,breast cancer prevails as the most common malignancy throughout the world.According to Surveillance,Epidemiology,and End Results(SEER)database,hormone receptor-positive(HR+)breast cancer accounts for more than 70%of all breast cancer patients.As well,endocrine therapy is one of the main modalities for the treatment of HR+ advanced breast cancer.Several studies have confirmed that endocrine therapy combined with CDK4/6 inhibitors can significantly improve the prognosis of HR+ advanced breast cancer.Currently CDK4/6 inhibitors including Palbociclib,Abemaciclib,and Ribociclib are applied in clinic.Dalpiciclib is the first CDK4/6 inhibitor independently developed by China,which is a class 1.1 innovative drug.In this article,we review relevant studies of Dalpiciclib in breast cancer,and provide references for Dalpiciclib in the future treatment of breast cancer.
Breast cancerDalpiciclibCyclin dependent kinase 4/6(CDK4/6)inhibitorsCurative effect
NETL
NSTL
万方数据
